Valuation: Alkermes plc

Capitalization 5.84B 5.56B 5.24B 4.63B 8.27B 506B 9.18B 62.4B 23.12B 211B 21.88B 21.44B 887B P/E ratio 2025 *
31x
P/E ratio 2026 * 31.9x
Enterprise value 5.51B 5.25B 4.95B 4.37B 7.81B 478B 8.67B 58.94B 21.84B 200B 20.67B 20.25B 838B EV / Sales 2025 *
3.95x
EV / Sales 2026 * 3.64x
Free-Float
90.15%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.31%
1 week+13.68%
Current month+13.83%
1 month+23.55%
3 months+27.31%
6 months+33.02%
Current year+24.79%
More quotes
1 week
31.01
Extreme 31.005
36.25
1 month
29.27
Extreme 29.27
36.25
Current year
27.70
Extreme 27.7
36.25
1 year
22.90
Extreme 22.9
36.25
3 years
21.75
Extreme 21.75
36.25
5 years
11.98
Extreme 11.98
36.25
10 years
11.98
Extreme 11.98
80.71
More quotes
Director TitleAgeSince
Chief Executive Officer 63 1991-01-31
Director of Finance/CFO 52 2024-01-31
Chief Tech/Sci/R&D Officer - 2004-12-31
Manager TitleAgeSince
Chairman 63 2011-08-31
Director/Board Member 73 2016-05-25
Director/Board Member 62 2018-03-29
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-0.31%+13.68%+10.23%+53.97% 5.84B
-0.43%-1.39%+28.71%-1.26% 47.89B
-1.33%-7.06%-19.89%-15.40% 34.06B
-0.45%-1.71%-0.38%+22.57% 26.65B
+0.04%+6.58%+72.73%+81.40% 16.54B
+1.95%-3.75%-35.82%-23.17% 15.37B
+6.79%+29.70% - - 14.08B
+3.35%+1.20%-63.80%-78.17% 12.7B
-1.12%-9.44%-7.47%-36.10% 10.42B
-0.65%-3.93%-13.74%+144.96% 10.36B
Average +0.78%+2.46%-3.27%+16.53% 19.39B
Weighted average by Cap. +0.36%+0.48%+2.05%+8.09%
See all sector performances

Financials

2025 *2026 *
Net sales 1.4B 1.33B 1.25B 1.11B 1.98B 121B 2.19B 14.92B 5.53B 50.55B 5.23B 5.13B 212B 1.45B 1.38B 1.31B 1.15B 2.06B 126B 2.29B 15.54B 5.76B 52.66B 5.45B 5.34B 221B
Net income 199M 190M 179M 158M 282M 17.27B 313M 2.13B 790M 7.22B 747M 732M 30.32B 200M 191M 180M 159M 284M 17.35B 315M 2.14B 793M 7.26B 751M 736M 30.46B
Net Debt -323M -307M -290M -256M -457M -27.96B -507M -3.45B -1.28B -11.69B -1.21B -1.19B -49.07B -544M -518M -488M -431M -771M -47.11B -855M -5.81B -2.15B -19.7B -2.04B -2B -82.7B
More financial data * Estimated data
Logo Alkermes plc
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Employees
1,800
More about the company
Date Price Change Volume
25-02-14 35.89 $ -0.31% 2,626,769
25-02-13 36.00 $ +7.46% 4,006,568
25-02-12 33.50 $ +4.82% 3,574,228
25-02-11 31.96 $ +2.34% 4,478,891
25-02-10 31.23 $ -1.08% 1,751,583

Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm EST

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
35.89USD
Average target price
36.43USD
Spread / Average Target
+1.50%
Consensus

Quarterly revenue - Rate of surprise